FDA gives once-yearly zoledronic acid injection expanded use.
The Food & Drug Administration has broadened the indication for zoledronic acid (Reclast, Novartis) to include the prevention of fractures in patients who’ve had a recent hip fracture. The decision was based on safety and efficacy data from the Recurrent Fracture Trial that showed an increase in bone mineral density and a 35% reduction in risk of new fractures in patients treated with the drug compared with placebo. According to the manufacturer, Reclast is given as a once-yearly 15-minute intravenous infusion and, when taken along with calcium and vitamin D supplements, helps to protect against fracture for a full year.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.